MYCN and neoplasm: In addition, we expanded this analysis for two primary patient-derived tumor cell lines (one MYCN amplified and one MYCN non-amplified organoid grown in stem cell medium) for which we tested viability for drug combinations after 5 days of treatment and observed even stronger synergism (Fig. 7b).